Dr. Yanguang Cao (currently Res. Ast. Prof., University at Buffalo), Minimal PBPK models for monoclonal antibodies
Dr. Gary Mo (Post-doctoral Fellow), Role of pharmacodynamic response in the clearance of drugs targeting membrane-bound
receptors
Weiyan Zhang, Ph.D., (post-doctoral fellow, University at Buffalo), In vivo mechanisms of drug-load release for antibody drug
conjugates (ADC) and their relationships to drug-related toxicity
Jie Zhao, Research Associate, Distribution of Etanercept to Sites of Inflammation in Collagen-Induced Arthritic Rats
Frank Engler, Ph.D. candidate, Evaluation of the influence of nephropathy on mAb disposition
Xi Chen, Ph.D. Candidate, Effects of inflammation on mAb pharmacokinetics and pharmacodynamics
Patrick Glassman, Ph.D. candidate, PBPK model of mAb disposition: Inclusion of mAb-target pH-dependent dissociation and
FcRn-mediated recycling
Tommy Li, Ph.D. candidate, Effects of immunosuppressive therapy on human FcRn expression in transgenic mice
Veena Thomas, Ph.D. candidate, Evaluation of mAb-receptor binding: Comparison of experimental methods and model-
based inference
Anas Fathallah, Ph.D. candidate, Determining immunogenicity risk associated with product aggregation and route of
administration
Jun Wang, Ph.D. candidate, ‘Tumor priming’ to enhance mAb penetration in pancreatic cancer
Gurkishan Chada, Ph.D. candidate, Effect of Type II diabetes mellitus and chronic kidney disease on antibody
pharmacokinetics
Anita Moein, M.S., candidate, Evaluation of mAb distribution to the brain: Non-invasive imaging vs. necropsy
Mark Bryniarski, Ph.D. candidate, Absorption mechanisms of monoclonal antibodies following oral delivery protected by
Cholestosomes(TM), using imaging of lymphatics to define absorption
Yang Chen, Ph.D. (currently employed at Novartis) Physiologically-based pharmacokinetic (PBPK) modeling of IgG
Qi (Nancy) Zhang, Ph.D. PK/PD/PG/DIS Models for Etanercept Interactions with Cytokines in a Rat Model of RA
Shang-Chiung Chen, Ph.D. (currently employed at Genentech) Investigation of the influence of FcRn recycling on the target-mediated
elimination of of anti-CEA monoclonal antibodies in mice
Xiaoyan Zhang, Ph.D. (Res. Ast. Prof., University of Florida) Investigation of the influence of Fc-gamma-R on the elimination of
monoclonal antibodies
John Harrold, Ph.D. (currently employed at Amgen) Multiscale Systems Analysis of Anti-CD20 mAb Pharmacodynamics
Leonid Kagan, Ph.D. (Ast. Prof., Rutgers University) Interferon-beta Biodisposition and Effects on Osteolytic Lesions
Lubna Abuqayyas, Ph.D. (currently employed at Amgen) PBPK modeling of the disposition of non-targeted and targeted antibodies
in SCID mice
Dr. Hoi Kei Lon (currently employed and AbbVie), Etanercept Pharmacokinetics in Collagen-Induced Arthritic Rats
Tao Ji, Ph.D. Use of accelerator mass spectrometry for investigating target ligand turnover kinetics
Bo Zheng, Ph.D.
Alison Gaudy, Ph.D. (currently employed at Celegene, Inc.) Influence of charged residues in the variable domain on half-life, tissue
distribution, and bioavailability of therapeutic IgG antibodies
Meric Ovacik, Ph.D. (currently employed at xxx) Algorithmic study design for identification of target expression from disposition data
|
